Telomir Pharmaceuticals (TELO) Institutional Ownership $4.81 -0.16 (-3.22%) (As of 12/26/2024 05:23 PM ET) Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Telomir Pharmaceuticals (NASDAQ:TELO)Number ofInstitutional Buyers(last 12 months)6TotalInstitutional Inflows(last 12 months)$1.88MNumber ofInstitutional Sellers(last 12 months)0 Get TELO Insider Trade Alerts Want to know when executives and insiders are buying or selling Telomir Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data TELO Institutional Buying and Selling by Quarter Ad DarwinHow Low-Cost Stocks Generate Monthly IncomeAre you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!👉 Yes, I Want the Free Report! 👈 Telomir Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/19/2024 Barclays PLC7,018$45K0.0%+325.1%0.024% 11/16/2024 Geode Capital Management LLC238,737$1.53M0.0%+259.8%0.806% 11/15/2024 Barclays PLC7,018$45K0.0%+325.1%0.024% 11/15/2024 State Street Corp36,094$232K0.0%+99.1%0.122% 10/21/2024 Suncoast Equity Management51,194$329K0.0%+109.9%0.173% 8/15/2024 Beaird Harris Wealth Management LLC14,623$70K0.0%+212.9%0.049% 7/26/2024 Bank of New York Mellon Corp50,165$241K0.0%N/A0.169% 5/2/2024 Suncoast Equity Management24,391$126K0.0%N/A0.082% (Data available from 1/1/2016 forward) TELO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of TELO shares? During the previous two years, the following institutional investors and hedge funds held shares of Telomir Pharmaceuticals shares: Geode Capital Management LLC ($1.53M), Suncoast Equity Management ($329K), Bank of New York Mellon Corp ($241K), State Street Corp ($232K), and Beaird Harris Wealth Management LLC ($70K), Barclays PLC ($45K).Learn more on TELO's institutional investors. Which institutional investors have been buying Telomir Pharmaceuticals stock? The following institutional investors have purchased Telomir Pharmaceuticals stock in the last 24 months: Geode Capital Management LLC ($172.38K), Suncoast Equity Management ($51.19K), Bank of New York Mellon Corp ($50.17K), State Street Corp ($17.97K), Barclays PLC ($10.73K), and Beaird Harris Wealth Management LLC ($9.95K). How much institutional buying is happening at Telomir Pharmaceuticals? Institutional investors have bought a total of 312,392 shares in the last 24 months. This purchase volume represents approximately $1.88M in transactions. Related Companies Altimmune Major Shareholders Tourmaline Bio Major Shareholders Ginkgo Bioworks Major Shareholders Astria Therapeutics Major Shareholders Mereo BioPharma Group Major Shareholders Phathom Pharmaceuticals Major Shareholders CorMedix Major Shareholders Xeris Biopharma Major Shareholders Terns Pharmaceuticals Major Shareholders Verve Therapeutics Major Shareholders This page (NASDAQ:TELO) was last updated on 12/27/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
